Compare DOMH & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | ADXN |
|---|---|---|
| Founded | 1967 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.2M | 10.3M |
| IPO Year | N/A | N/A |
| Metric | DOMH | ADXN |
|---|---|---|
| Price | $4.28 | $8.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 341.3K | 3.2K |
| Earning Date | 11-10-2025 | 12-04-2025 |
| Dividend Yield | ★ 13.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 9.19 | N/A |
| Revenue | ★ $99,588,000.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.52 | ★ N/A |
| Revenue Growth | ★ 691.07 | N/A |
| 52 Week Low | $1.00 | $6.51 |
| 52 Week High | $13.58 | $12.05 |
| Indicator | DOMH | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 50.06 |
| Support Level | $4.20 | $7.72 |
| Resistance Level | $5.10 | $8.90 |
| Average True Range (ATR) | 0.29 | 0.35 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 11.11 | 57.14 |
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.